Explore Latest Offerings in the mRNA Vaccine Raw Materials Market with Company Updates
| Company | Description |
| Thermo Fisher Scientific Inc. | This mainly explores a comprehensive, cGMP-compliant portfolio of raw materials for mRNA vaccine development, characterising their high-purity TheraPure reagents. |
| Merck KGaA (MilliporeSigma) | A firm facilitates a comprehensive, end-to-end portfolio of raw materials, reagents, and services for the complete mRNA vaccine manufacturing process, from pre-clinical development to commercial production. |
| Maravai LifeSciences (TriLink BioTechnologies) | This specifically offers GMP-grade raw materials for mRNA vaccines, specializing in proprietary CleanCap capping analogs. |
| Aldevron (Danaher Corporation) | It usually specializes in the production of high-quality plasmid DNA, mRNA, and proteins for vaccines and therapeutics |
| New England Biolabs (NEB) | A company provides a comprehensive portfolio of high-quality, research-grade, and GMP-grade reagents for the complete mRNA vaccine production process. |
| Jena Bioscience GmbH | This offers modified nucleoside triphosphates, high-concentration T7 RNA polymerases, and precision HighYield T7 synthesis kits. |
| Promega Corporation | It is prominently emphasizing high-quality, animal-origin-free (AOF) components, favourable for cGMP processes. |
| Hongene Biotech | A firm explores extensive nucleosides, nucleotides, phosphoramidites, cap analogs, and lipids. |
| Yeasen Biotechnology | Its offerings comprise T7 RNA polymerase, capping enzymes (Vaccinia Capping Enzyme, 2'-O-Methyltransferase), RNA cleaners, and modified nucleoside triphosphates (NTPs). |
| BOC Sciences | This majorly explores cGMP and non-GMP grade materials, which assist the full mRNA production workflow. |
Market Growth and Overview
The mRNA vaccine raw materials market is experiencing significant expansion, with projections indicating a revenue increase reaching several hundred million dollars by the end of the forecast period, spanning 2026 to 2035. This growth is driven by emerging trends and strong demand across key sectors.
Nowadays, the world is facing a huge burden of diverse infectious diseases and cancer cases, which is highly demanding advanced mRNA vaccines & therapeutics. This further boost adoption of highly pure, scalable raw materials and the latest production technologies & component, like LNP technology, capping agents, and modified nucleotides.
What are the Recent Developments in the mRNA Vaccine Raw Materials Market?
- In November 2025, Primrose Bio, Inc. unveiled Prima RNApols ExTend Cap AU, an RNA polymerase engineered to enhance the production of self-amplifying mRNA vaccines and therapeutics.
- In September 2025, Elegen introduced ENFINIA IVT Ready DNA for immediate use in in vitro transcription (IVT), raising the development of mRNA-based therapeutics by weeks.
Need all your mRNA vaccine raw material market data and insights in one place? Checkout Your Smart Dashboard Now
Keypoints
- Company Overview
- Locations Subsidiaries/Geographic reach
- Key Executives
- Company Financials
- Patents registered
- SWOT Analysis
- Applications Catered
- Strategic collaborations
- Recent Developments
- Competitive Benchmarking
